表紙
市場調查報告書

臨床霉漿菌屬檢驗的全球市場:產業趨勢·預測

Global Mycoplasma Testing in Clinical Market: Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 904406
出版日期 內容資訊 英文 367 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
臨床霉漿菌屬檢驗的全球市場:產業趨勢·預測 Global Mycoplasma Testing in Clinical Market: Industry Trends and Forecast to 2026
出版日期: 2019年07月01日內容資訊: 英文 367 Pages
簡介

本報告提供全球臨床霉漿菌屬檢驗市場相關調查分析,提供市場概要,市場趨勢,各市場區隔的市場分析,各地區預測,主要企業等相關的系統性資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 全球臨床霉漿菌屬檢驗市場:各產品

  • 概要
  • 套件·試劑
  • 設備
  • 服務

第7章 全球臨床霉漿菌屬檢驗市場:各技術

  • 概要
  • 微生物培養/直接化驗
  • 聚合酵素鏈鎖反應 (PCR)
  • ELISA
  • DNA染色/間接化驗
  • 酵素法
  • 其他

第8章 全球臨床霉漿菌屬檢驗市場:各疾病領域

  • 概要
  • 呼吸系統
  • 泌尿生殖系統
  • 腸胃
  • 心血管
  • 肌肉骨骼
  • 其他

第9章 全球臨床霉漿菌屬檢驗市場:各終端用戶

  • 概要
  • 醫院
  • 臨床檢驗室
  • 其他

第10章 全球臨床霉漿菌屬檢驗市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第11章 全球臨床霉漿菌屬檢驗市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第12章 企業簡介

  • BIO-RAD LABORATORIES, INC.
  • MERCK KGAA
  • BIOMERIEUX SA
  • SARTORIUS AG
  • AB ANALITICA SRL
  • AGILENT TECHNOLOGIES, INC.
  • ELITECHGROUP
  • GOLD STANDARD DIAGNOSTICS
  • LIOFILCHEM SRL
  • LONZA
  • OPERON
  • OSANG HEALTHCARE
  • PROMOCELL GMBH
  • F. HOFFMANN-LA ROCHE LTD
  • SACACE BIOTECHNOLOGIES SRL
  • SEEGENE INC.
  • THERMO FISHER SCIENTIFIC INC.
  • ZEAKON DIAGNOSTICS

第13章 結論

第14章 詢問調查

第15章 相關調查

目錄

Global mycoplasma testing in clinical market is projected to register a healthy CAGR of 12.6% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026

Market Segmentation

By Products (Kits and Reagents, Instruments, Services), Technique (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods, Others), Disease Area (Respiratory, Urogenital, Gastrointestinal, Cardiovascular, Musculoskeletal, Others), End User (Diagnostic Laboratories, Hospitals, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Some of the major factors contributing to the growth of global mycoplasma testing in clinical market are:

  • Investment in R&D activities by pharmaceutical and biotechnology companies
  • Growing initiatives by Government and Associations

Market Players:

The key market players for global mycoplasma testing in clinical market are listed below:

  • Sartorius AG
  • MERCK KGAA
  • ELITechGROUP
  • AB ANALITICA srl
  • GOLD STANDARD DIAGNOSTICS
  • OSANG Healthcare
  • BioFire Diagnostics
  • PromoCell GmbH
  • Lonza
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Liofilchem Srl
  • ZEAKON Diagnostics
  • OPERON
  • Bio-Rad Laboratories, Inc.
  • Sacace Biotechnologies Srl
  • Seegene Inc.
  • others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.6 DBMR MARKET POSITION GRID
  • 2.7 DBMR VENDOR SHARE ANALYSIS
  • 2.8 MULTIVARIATE MODELING
  • 2.9 PRODUCTS LIFELINE CURVE
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INVESTMENT IN R&D ACTIVITIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 3.1.2 RISING NUMBER OF DISEASES
    • 3.1.3 GROWING GOVERNMENT INITIATIVES
  • 3.2 RESTRAINTS
    • 3.2.1 HIGH COST OF INSTRUMENTS
    • 3.2.2 STRINGENT GOVERNMENT REGULATIONS
  • 3.3 OPPORTUNITIES
    • 3.3.1 AVAILIBILITY OF NUMBER OF TECHNIQUES FOR DETECTION OF MYCOPLASMA
    • 3.3.2 STRATEGIC INITIATIVES BY VARIOUS COMPANIES
  • 3.4 CHALLENGES
    • 3.4.1 LACK OF SKILLED PROFESSIONALS
    • 3.4.2 CHALLENEGES IN THE DIAGNOSIS OF MYCOPLASMA INFECTION

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS

  • 6.1 OVERVIEW
  • 6.2 KITS & REAGENTS
  • 6.3 INSTRUMENTS
  • 6.4 SERVICES

7 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES

  • 7.1 OVERVIEW
  • 7.2 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
  • 7.3 POLYMERASE CHAIN REACTION
  • 7.4 ELISA
  • 7.5 DNA STAINING/INDIRECT ASSAY
  • 7.6 ENZYMATIC METHODS
  • 7.7 OTHERS

8 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA

  • 8.1 OVERVIEW
  • 8.2 RESPIRATORY
    • 8.2.1 BY CAUSATIVE AGENT
      • 8.2.1.1 MYCOPLASMA PNEUMONIAE
      • 8.2.1.2 MYCOPLASMA HOMINIS
      • 8.2.1.3 UREAPLASMA UREALYTICUM
      • 8.2.1.4 MYCOPLASMA GENITALIUM
      • 8.2.1.5 OTHERS
    • 8.2.2 BY TECHNIQUE
      • 8.2.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.2.2.2 POLYMERASE CHAIN REACTION
      • 8.2.2.3 ELISA
      • 8.2.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.2.2.5 ENZYMATIC METHODS
      • 8.2.2.6 OTHERS
  • 8.3 UROGENITAL
    • 8.3.1 BY CAUSATIVE AGENT
      • 8.3.1.1 MYCOPLASMA HOMINIS
      • 8.3.1.2 UREAPLASMA UREALYTICUM
      • 8.3.1.3 MYCOPLASMA GENITALIUM
      • 8.3.1.4 MYCOPLASMA PNEUMONIAE
      • 8.3.1.5 OTHERS
    • 8.3.2 BY TECHNIQUE
      • 8.3.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.3.2.2 POLYMERASE CHAIN REACTION
      • 8.3.2.3 ELISA
      • 8.3.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.3.2.5 ENZYMATIC METHODS
      • 8.3.2.6 OTHERS
  • 8.4 GASTROINTESTINAL
    • 8.4.1 BY CAUSATIVE AGENT
      • 8.4.1.1 MYCOPLASMA PNEUMONIAE
      • 8.4.1.2 MYCOPLASMA HOMINIS
      • 8.4.1.3 UREAPLASMA UREALYTICUM
      • 8.4.1.4 MYCOPLASMA GENITALIUM
      • 8.4.1.5 OTHERS
    • 8.4.2 BY TECHNIQUE
      • 8.4.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.4.2.2 POLYMERASE CHAIN REACTION
      • 8.4.2.3 ELISA
      • 8.4.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.4.2.5 ENZYMATIC METHODS
      • 8.4.2.6 OTHERS
  • 8.5 CARDIOVASCULAR
    • 8.5.1 BY CAUSATIVE AGENT
      • 8.5.1.1 MYCOPLASMA PNEUMONIAE
      • 8.5.1.2 MYCOPLASMA HOMINIS
      • 8.5.1.3 UREAPLASMA UREALYTICUM
      • 8.5.1.4 MYCOPLASMA GENITALIUM
      • 8.5.1.5 OTHERS
    • 8.5.2 BY TECHNIQUE
      • 8.5.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.5.2.2 POLYMERASE CHAIN REACTION
      • 8.5.2.3 ELISA
      • 8.5.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.5.2.5 ENZYMATIC METHODS
      • 8.5.2.6 OTHERS
  • 8.6 MUSCULOSKELETAL
    • 8.6.1 BY CAUSATIVE AGENT
      • 8.6.1.1 MYCOPLASMA PNEUMONIAE
      • 8.6.1.2 MYCOPLASMA HOMINIS
      • 8.6.1.3 UREAPLASMA UREALYTICUM
      • 8.6.1.4 MYCOPLASMA GENITALIUM
      • 8.6.1.5 OTHERS
    • 8.6.2 BY TECHNIQUE
      • 8.6.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.6.2.2 POLYMERASE CHAIN REACTION
      • 8.6.2.3 ELISA
      • 8.6.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.6.2.5 ENZYMATIC METHODS
      • 8.6.2.6 OTHERS
  • 8.7 OTHERS
    • 8.7.1 BY CAUSATIVE AGENT
      • 8.7.1.1 MYCOPLASMA PNEUMONIAE
      • 8.7.1.2 MYCOPLASMA HOMINIS
      • 8.7.1.3 UREAPLASMA UREALYTICUM
      • 8.7.1.4 MYCOPLASMA GENITALIUM
      • 8.7.1.5 OTHERS
    • 8.7.2 BY TECHNIQUE
      • 8.7.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY
      • 8.7.2.2 POLYMERASE CHAIN REACTION
      • 8.7.2.3 ELISA
      • 8.7.2.4 DNA STAINING/INDIRECT ASSAY
      • 8.7.2.5 ENZYMATIC METHODS
      • 8.7.2.6 OTHERS

9 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER

  • 9.1 OVERVIEW
  • 9.2 HOSPITALS
  • 9.3 DIAGNOSTIC LABORATORIES
  • 9.4 OTHERS

10 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY GEOGRAPHY

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 U.S.
    • 10.2.2 CANADA
    • 10.2.3 MEXICO
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 U.K.
    • 10.3.3 FRANCE
    • 10.3.4 ITALY
    • 10.3.5 SPAIN
    • 10.3.6 NETHERLANDS
    • 10.3.7 SWITZERLAND
    • 10.3.8 RUSSIA
    • 10.3.9 BELGIUM
    • 10.3.10 TURKEY
    • 10.3.11 REST OF EUROPE
  • 10.4 ASIA-PACIFIC
    • 10.4.1 JAPAN
    • 10.4.2 CHINA
    • 10.4.3 INDIA
    • 10.4.4 SOUTH KOREA
    • 10.4.5 AUSTRALIA
    • 10.4.6 SINGAPORE
    • 10.4.7 MALAYSIA
    • 10.4.8 INDONESIA
    • 10.4.9 THAILAND
    • 10.4.10 PHILIPPINES
    • 10.4.11 REST OF ASIA-PACIFIC
  • 10.5 SOUTH AMERICA
    • 10.5.1 BRAZIL
    • 10.5.2 REST OF SOUTH AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 SOUTH AFRICA
    • 10.6.2 REST OF MIDDLE EAST & AFRICA

11 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, COMPANY LANDSCAPE

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 11.3 COMPANY SHARE ANALYSIS: EUROPE
  • 11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

12 COMPANY PROFILE

  • 12.1 BIO-RAD LABORATORIES, INC.
    • 12.1.1 COMPANY SNAPSHOT
    • 12.1.2 REVENUE ANALYSIS
    • 12.1.3 COMPANY SHARE ANALYSIS
    • 12.1.4 PRODUCT PORTFOLIO
    • 12.1.5 RECENT DEVELOPMENTS
  • 12.2 MERCK KGAA
    • 12.2.1 COMPANY SNAPSHOT
    • 12.2.2 REVENUE ANALYSIS
    • 12.2.3 COMPANY SHARE ANALYSIS
    • 12.2.4 PRODUCT PORTFOLIO
    • 12.2.5 RECENT DEVELOPMENT
  • 12.3 BIOMERIEUX SA
    • 12.3.1 COMPANY SNAPSHOT
    • 12.3.2 REVENUE ANALYSIS
    • 12.3.3 COMPANY SHARE ANALYSIS
    • 12.3.4 PRODUCT PORTFOLIO
    • 12.3.5 RECENT DEVELOPMENTS
  • 12.4 SARTORIUS AG
    • 12.4.1 COMPANY SNAPSHOT
    • 12.4.2 REVENUE ANALYSIS
    • 12.4.3 COMPANY SHARE ANALYSIS
    • 12.4.4 PRODUCT PORTFOLIO
    • 12.4.5 RECENT DEVELOPMENTS
  • 12.5 AB ANALITICA SRL
    • 12.5.1 COMPANY SNAPSHOT
    • 12.5.2 PRODUCT PORTFOLIO
    • 12.5.3 RECENT DEVELOPMENTS
  • 12.6 AGILENT TECHNOLOGIES, INC.
    • 12.6.1 COMPANY SNAPSHOT
    • 12.6.2 REVENUE ANALYSIS
    • 12.6.3 PRODUCT PORTFOLIO
    • 12.6.4 RECENT DEVELOPMENTS
  • 12.7 ELITECHGROUP
    • 12.7.1 COMPANY SNAPSHOT
    • 12.7.2 PRODUCT PORTFOLIO
    • 12.7.3 RECENT DEVELOPMENTS
  • 12.8 GOLD STANDARD DIAGNOSTICS
    • 12.8.1 COMPANY SNAPSHOT
    • 12.8.2 PRODUCT PORTFOLIO
    • 12.8.3 RECENT DEVELOPMENTS
  • 12.9 LIOFILCHEM SRL
    • 12.9.1 COMPANY SNAPSHOT
    • 12.9.2 PRODUCT PORTFOLIO
    • 12.9.3 RECENT DEVELOPMENTS

  • 12.10 LONZA
    • 12.10.1 COMPANY SNAPSHOT
    • 12.10.2 REVENUE ANALYSIS
    • 12.10.3 PRODUCT PORTFOLIO
    • 12.10.4 RECENT DEVELOPMENTS
  • 12.11 OPERON
    • 12.11.1 COMPANY SNAPSHOT
    • 12.11.2 PRODUCT PORTFOLIO
    • 12.11.3 RECENT DEVELOPMENTS
  • 12.12 OSANG HEALTHCARE
    • 12.12.1 COMPANY SNAPSHOT
    • 12.12.2 PRODUCT PORTFOLIO
    • 12.12.3 RECENT DEVELOPMENT
  • 12.13 PROMOCELL GMBH
    • 12.13.1 COMPANY SNAPSHOT
    • 12.13.2 PRODUCT PORTFOLIO
    • 12.13.3 RECENT DEVELOPMENTS
  • 12.14 F. HOFFMANN-LA ROCHE LTD
    • 12.14.1 COMPANY SNAPSHOT
    • 12.14.2 REVENEUE ANALYSIS
    • 12.14.3 PRODUCT PORTFOLIO
    • 12.14.4 RECENT DEVELOPMENTS
  • 12.15 SACACE BIOTECHNOLOGIES SRL
    • 12.15.1 COMPANY SNAPSHOT
    • 12.15.2 PRODUCT PORTFOLIO
    • 12.15.3 RECENT DEVELOPMENT
  • 12.16 SEEGENE INC. (2018)
    • 12.16.1 COMPANY SNAPSHOT
    • 12.16.2 REVENUE ANALYSIS
    • 12.16.3 PRODUCT PORTFOLIO
    • 12.16.4 RECENT DEVELOPMENTS
  • 12.17 THERMO FISHER SCIENTIFIC INC.
    • 12.17.1 COMPANY SNAPSHOT
    • 12.17.2 REVENUE ANALYSIS
    • 12.17.3 PRODUCT PORTFOLIO
    • 12.17.4 RECENT DEVELOPMENT
  • 12.18 ZEAKON DIAGNOSTICS
    • 12.18.1 COMPANY SNAPSHOT
    • 12.18.2 PRODUCT PORTFOLIO
    • 12.18.3 RECENT DEVELOPMENT

13 SWOT AND DBMR ANALYSIS

14 CONCLUSION:

15 QUESTIONNAIRE

16 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: SEGMENTATION
  • FIGURE 2 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: DATA VALIDATION MODEL
  • FIGURE 3 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: GLOBAL VS REGIONAL
  • FIGURE 5 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET
  • FIGURE 10 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: SEGMENTATION
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 12 INCREASING CASES OF MYCOPLASMA INFECTIONS AND TECHNOLOGIAL ADVANCEMENTS IN THE IDENTIFICATION TECHNIQUES ARE EXPECTED TO DRIVE THE GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 13 KITS & REAGENTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 & 2026
  • FIGURE 14 ASIA-PACIFIC IS THE MAXIMUM GROWING AND NORTH AMERICA IS THE MOST PROFITABLE REVENUE POCKETS FOR GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 15 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY TYPE, 2018
  • FIGURE 16 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY TECHNIQUES, 2018
  • FIGURE 17 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY DISEASE AREA, 2018
  • FIGURE 18 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY END USER, 2018
  • FIGURE 19 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 20 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY GEOGRAPHY (2018)
  • FIGURE 21 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 22 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 23 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019 - 2026)
  • FIGURE 24 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 25 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
  • FIGURE 26 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 27 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 28 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
  • FIGURE 29 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 30 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
  • FIGURE 31 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 32 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 33 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
  • FIGURE 34 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 35 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
  • FIGURE 36 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 37 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 38 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
  • FIGURE 39 SOUTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 40 SOUTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
  • FIGURE 41 SOUTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 42 SOUTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 43 SOUTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
  • FIGURE 44 MIDDLE EAST & AFRICA MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
  • FIGURE 45 MIDDLE EAST & AFRICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
  • FIGURE 46 MIDDLE EAST & AFRICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 47 MIDDLE EAST & AFRICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 48 MIDDLE EAST & AFRICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
  • FIGURE 49 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 50 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 51 EUROPE MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 52 ASIA-PACIFIC MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)
Back to Top